Trial · NCT07134205
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival (PFS) | Up to approximately 3 years | defined as the time from randomization to the first occurrence of disease progression as determined by the BIRC with use of RECIST v1.1 or death from any cause, whichever occurs first. |
| Secondary | Overall response rate (ORR) | Up to approximately 2 years | determined by the BIRC and investigator with use of RECIST v1.1 |
| Secondary | Disease Control Rate (DCR) | Up to approximately 2 years | determined by the BIRC and investigator with use of RECIST v1.1 |
| Secondary | Duration of response (DOR) | Up to approximately 2 years | determined by the BIRC and investigator with use of RECIST v1.1 |
| Secondary | Progression-free Survival (PFS) | Up to approximately 2 years | defined as the time from randomization to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | Up to approximately 5 years | Duration from the date of initial treatment to the date of death due to any cause. |
| Secondary | Incidence and severity of AEs | Up to approximately 2 years | Incidence and severity of adverse events (AE). Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0. |
| Secondary | Serum concentration of JMT101 | Up to approximately 2 years | Serum concentration and immunogenicity of JMT101 |
| Secondary | Serum immunogenicity of JMT101 | Up to approximately 2 years | Immunogenicity of JMT101 |
| Secondary | To be assessed by European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L). | Up to approximately 2 years | use EORTC QLQ-C30 questionnaire and the EQ-5D-5L questionnaire |
| Secondary | Drug resistance | Up to approximately 2 years | Gene Variations Detected by ctDNA and Drug Resistance Biomarkers |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07134205/registered